Marqueur diagnostique pour le cancer

Diagnostische marker für krebs

Diagnostic marker for cancer


Es wird die Verwendung verschiedener Proteine als diagnostische Marker für Krebserkrankungen bereitgestellt. Besonders bevorzugt ist die Verwendung des Proteins Annexin A3. Bevorzugterweise wird hierbei eine Heraufregulation von Annexin A3 im Vergleich mit Kontrollen untersucht. Weiterhin wird die Verwendung von Wirkstoffen zur Herstellung eines Medikaments zur Behandlung von Krebs beschrieben, wobei diese Wirkstoffe die Aktivität und/oder die Abundanz verschiedener charakteristischer Proteine beeinflussen.
The invention relates to the use of various proteins as diagnostic markers for cancerous diseases. In particular, the use of the annexin A3 protein is preferred. Preferably an increased regulation of annexin A3 is analysed in comparison to controls. The invention also relates to the use of active substances for producing a medicament used in the treatment of cancer, said substances influencing the activity and/or abundance of various characteristic proteins.
L'invention concerne l'utilisation de diverses protéines comme marqueurs diagnostiques pour des maladies cancéreuses. On mentionne, de préférence, plus particulièrement l'utilisation de l'annexine A3. De préférence, une régulation accrue de l'annexine A3 est analysée en comparant avec des témoins. L'invention concerne en outre l'utilisation de substances actives pour la production d'un médicament pour le traitement du cancer, lesdites substances actives influençant l'activité et/ou l'abondance de protéines caractéristiques variées.




Download Full PDF Version (Non-Commercial Use)

Patent Citations (5)

    Publication numberPublication dateAssigneeTitle
    US-2002119463-A1August 29, 2002Mary Faris, Turner Christopher M.Prostate cancer markers
    US-2003108963-A1June 12, 2003Millennium Pharmaceuticals, Inc., Mayo Foundation For Medical Education And ResearchNovel genes, compositions, kit, and methods for identification, assessment, prevention and therapy of prostate cancer
    US-2003180738-A1September 25, 2003Rees Robert Charles, Geng Li, Shahid MianCancer associated genes and their products
    US-2003185808-A1October 02, 2003Peter Thraves, Andrew SuttonProstate cell lines
    US-6476207-B1November 05, 2002Chiron CorporationGenes and gene expression products that are differentially regulated in prostate cancer

NO-Patent Citations (3)

    GRANER EDGARD ET AL: "The isopeptidase USP2a regulates the stability of fatty acid synthase in prostate cancer", CANCER CELL, vol. 5, no. 3, March 2004 (2004-03-01), pages 253 - 261, XP002340626, ISSN: 1535-6108
    HOFMANN E A: "Interactions of benzodiazepine drivatives with annexins", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD, US, vol. 273, no. 5, 30 January 1998 (1998-01-30), pages 2885 - 2894, XP002098631, ISSN: 0021-9258
    VAARALA M H ET AL: "Differentially expressed genes in two LNCaP prostate cancer cell lines REFLECTING CHANGES DURING PROSTATE CANCER PROGRESSION", LABORATORY INVESTIGATION, UNITED STATES AND CANADIAN ACADEMY OF PATHOLOGY, BALTIMORE,, US, vol. 80, no. 8, August 2000 (2000-08-01), pages 1259 - 1268, XP002225395, ISSN: 0023-6837

Cited By (0)

    Publication numberPublication dateAssigneeTitle